HCW Biologics is trading at $1.83, down 5.18%, in after-hours trading, as dilution concerns follow its private-placement announcement. - On September 25, 2026, shares fell 3.02% in the regular session; the company announced the $1.5 million placement on September 24. - The placement includes 903,614 units with pre-funded warrants and potential common warrants, priced at $1.6599 per unit; stockholder approval is required for the common warrants. - Proceeds are intended to fund clinical trials and other corporate purposes.